Document is current
Any future updates will be listed below
-
Authors
Wan, Peter Kok-Ting
Cheng, Ranchu
Johnson, David
Lee, Carl
Wu, Shihong
Mian, Areeb
Hazini, Ahmet
Moradi, Sorayya
Friesen, Kate
Caviezel, Flurin
Abbas, Syed Hussain
Nicholls, Brannon
Sadik, Hatem
Lakha, Adil
Jones, Keaton
Kumaran, Girishkumar
Bottomley, Matthew J.
Jones, Rob
Coles, Mark
Bashford-Rogers, Rachael
Coussios, Constantin
Seymour, Len
Carlisle, Robert
Fisher, Kerry
Gordon-Weeks, Alex
-
Funding
Funding for this research was provided by:
Cancer Research UK (DRCPGM-Jun25/100008)
Theolytics Ltd
The Lee Placito Fellowship
- License Information
-
More Information
Article History
Received: 11 March 2026
Accepted: 24 June 2026
First Online: 20 July 2026
Declarations
Ethics approval and consent to participate: All tissues were retrieved from patients undergoing surgical resection of liver metastatic colorectal cancer within the Department of Hepatobiliary Surgery, Oxford, UK and Department of Hepatobiliary Surgery, Liverpool, UK. Tissues were collected under ethics numbers 22/SC/0429 and 21/YH/0206. The clinical details of patients in the CosMx and Cell DIVE datasets and those in hemi-liver perfusion experiments are shown in supplementary Tables 1–3 respectively.
Consent for publication: Not applicable.
Competing interests: RB-R: R.J.M.B.-R. is a co-founder and consultant of Alchemab Therapeutics Ltd.CC: CCC is a co-founder, director, shareholder, and receives consultancy income from OrganOx Ltd, the company that developed and commercialized for the purposes of organ preservation prior to transplantation the normothermic liver perfusion device used in the current research.
